News

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

Potential Indication Expansion for Telix’s Core Kidney Cancer Theranostic Program


Melbourne (Australia) and Liège (Belgium) – 5 October 2021. Telix announces that a first patient has been dosed in a Phase II study of TLX250-CDx in patients with triple-negative breast cancer 

Telix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France. 

‘OPALESCENCE’, an investigator-led study being undertaken by Dr. Caroline Rousseau at ICO, aims to evaluate how carbonic anhydrase IX (CA9imaging with positron emission tomography (PET) can be utilised for diagnosis and staging of TNBC and to develop a deeper understanding of CA9 as a potential therapeutic target in this patient population. The study will enrol 12 patients. TNBC has a poorer prognosis than other breast cancer subtypes and is characterised by its aggressive behaviour and distinct patterns of metastasis. There is a major unmet need due to the lack of targeted therapies for TNBC.  

CA9 is a transmembrane protein that is highly over-expressed in clear cell renal cancer (ccRCC) as well as a number of other different cancer types, making it an attractive potential target for both new imaging and therapeutic modalities. Telix’s core CA9 program is focused on ccRCC, the most common form of kidney cancer, and is the subject of the ZIRCON Phase III (imaging) and STARLITE  Phase II (therapy) studies. OPALESCENCE is the second in a comprehensive series of studies that will evaluate CA9 expression in cancers other than ccRCC, supporting Telix’s goal to rapidly expand the CA9 program into other indications. A study targeting CA9 in urothelial carcinoma or bladder cancer is underway with other collaborations being developed for ovarian, colorectal, head and neck, lung, and pancreatic cancers. 

Telix Chief Medical Officer, Dr. Colin Hayward stated, “Telix is very pleased to see a first patient dosed in this important study of TLX250-CDx in TNBC, an aggressive breast cancer subtype that is poorly served by current tracers. Should the targeting properties of this PET/CT imaging tracer be established in TNBC, our intention is to broaden future applications for Telix’s lutetium-177 and actinium-225 based CA9 therapies. We would like to express our gratitude to Dr. Caroline Rousseau and her clinical team at ICO, as well as the patients that will contribute to this ground-breaking study.” 

Principal Investigator for the OPALESCENCE study, Dr. Caroline Rousseau stated, “Theranostic approaches to diagnosis and treatment are transforming prostate cancer. Triple negative breast cancer has a poor prognosis, so the potential to identify new targets with potential theranostic approaches for these patients is very exciting.” 

To read the full media release please click here.

To return to Telix’s homepage please click here.

More Articles

ASX News

Activities Report and Appendix 4C for September 2021 Quarter

Melbourne (Australia) – 21 October 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.

Corporate Spotlight

Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021

15 October 2021 – Clinical Spotlight | Telix Satellite Symposium at the European Association of Nuclear Medicine 2021 Virtual Conference.

Corporate Spotlight

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

Potential Indication Expansion for Telix’s Core Kidney Cancer Theranostic Program Melbourne (Australia) and Liège (Belgium) – 5 October 2021. Telix announces...

Corporate Spotlight

Telix Establishes Commercial Hub in Geneva, Switzerland

Melbourne (Australia) and Geneva (Switzerland) – 4 October 2021. Telix announces that it has established a new commercial hub in...

Corporate Spotlight

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 September 2021. Telix welcomes SNMMI updated Appropriate Use Criteria for PSMA PET...

Corporate Spotlight

Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer

16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis...

ASX News

NCCN Guidelines Updated to Include PSMA-PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes...

ASX News

FDA Approves Phase II Kidney Cancer Therapy Study

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix announces the FDA has accepted the IND Application to...

ASX News

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate...

ASX News

Japanese Prostate Cancer Imaging Study Completes Enrolment

Melbourne (Australia) and Kyoto (Japan) – 9 September 2021. Telix has completed a Phase I clinical trial of TLX591-CDx for...

ASX News

Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics

Melbourne (Australia), Indianapolis (IN, U.S.A.), and Kettering (OH, U.S.A.) – 7 September 2021. Telix announces collaboration with Kettering Health on...

ASX News

Telix and Lightpoint Medical to Collaborate on Radioguided Surgery

Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI®...

ASX News

Telix Half-Year Results 2021 and Company Update Conference Call

Melbourne (Australia) – 19 August 2021. Telix announces Half-Year Results 2021 and provides shareholder update

ASX News

Telix Expands Prostate Cancer Activity with GenesisCare Collaboration

Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase...

ASX News

Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.

ASX News

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Melbourne (Australia) – 18 August 2021. Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx...

ASX News

Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®

Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being...

ASX News

Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia

Melbourne (Australia) and London (United Kingdom) – 17 August 2021. Telix announces Phase II academic study of TLX66 in children...

ASX News

Telix H1 2021 Results and Company Update Conference Call

Melbourne (Australia) – 11 August 2021. Telix to hold investor conference call to present H1 2021 financial results and Company...

ASX News

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study...

Corporate Spotlight

Ms. Helen Hovenga Joins Telix as Chief People Officer

4 August 2021 - Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief...

ASX News

Telix Seneffe Production Facility: Progress Update

Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...

ASX News

Activities Report and Appendix 4C for June 2021 Quarter

Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...

ASX News

ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update

Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...

Corporate Spotlight

Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA

19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...

Corporate Spotlight

Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...

ASX News

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...

ASX News

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...

ASX News

Telix Update on FDA New Drug Application Review for Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....

Corporate Spotlight

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...

Corporate Spotlight

Telix launches “Gallium Wave” Awareness Website

Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...

Corporate Spotlight

Scott Law joins Telix as SVP Global Manufacturing Operations

11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations

ASX News

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...

Corporate Spotlight

Telix to Present IPAX-1 Study in Glioblastoma at CNS Annual Meeting 2021

15 October 2021 - Corporate Spotlight | Telix to Present IPAX-1 Study in Glioblastoma Treatment at the Congress of Neurological...